Federal University of Bahia, Salvador, Bahia, Brazil.
Pain Manag. 2024;14(8):453-463. doi: 10.1080/17581869.2024.2401769. Epub 2024 Sep 20.
This study aims to assess the efficacy of low-dose naltrexone (LDN) in treating chronic pain. We conducted a systematic review using the PICO strategy: (P) Patients with chronic pain, (I) Use of oral naltrexone, (C) Placebo or active drug and (O) Pain relief and quality of life. We included articles from PubMed, Scopus, Cochrane CENTRAL and EMBASE databases. Seven randomized clinical trials involving 406 patients were analyzed. The doses ranging from 2 to 4.5 mg once daily across all studies. Various chronic pain conditions were evaluated. The results suggest that low-dose naltrexone is not effective in managing chronic pain and improving the quality of life in patients with diverse chronic pain conditions. However, further research with larger sample sizes and standardized methodologies is necessary.
本研究旨在评估低剂量纳曲酮(LDN)治疗慢性疼痛的疗效。我们采用 PICO 策略进行了系统评价:(P)慢性疼痛患者,(I)口服纳曲酮,(C)安慰剂或活性药物,(O)疼痛缓解和生活质量。我们纳入了来自 PubMed、Scopus、Cochrane CENTRAL 和 EMBASE 数据库的文章。分析了涉及 406 名患者的 7 项随机临床试验。所有研究中纳曲酮的剂量范围为每天 2 至 4.5 毫克。评估了各种慢性疼痛病症。结果表明,低剂量纳曲酮对于管理慢性疼痛和改善不同慢性疼痛病症患者的生活质量没有效果。然而,需要进一步进行具有更大样本量和标准化方法的研究。